Sunday 13 July 2014
Ibrutinib is an inhibitor of the enzyme Bruton’s tyrosine kinase (BTK). Ibrutinib is currently under development by Pharmacyclics, Inc and Johnson & Johnson’s Janssen Pharmaceutical division for additional B-cell malignancies including diffuse large B-cell lymphoma and multiple myeloma. It is an orally-administered, selective and covalent inhibitor of the enzyme Bruton’s tyrosine kinase (BTK).
Ibrutinib, (also known as PCI-32765 and marketed in the U.S. under the name Imbruvica) is an anticancer drug targeting B-cell malignancies.
It was approved by the US FDA and UE for the treatment of mantle cell lymphoma (MCL) and for the treatment of chronic lymphocytic leukemia (CLL).
Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation.
Wang A, Yan XE, Wu H, Wang W, Hu C, Chen C, Zhao Z, Zhao P, Li X, Wang L, Wang B, Ye Z, Wang J, Wang C, Zhang W, Gray NS, Weisberg EL, Chen L, Liu J, Yun CH, Liu Q.
Oncotarget. 2016 Sep 10. doi : 10.18632/oncotarget.11951 PMID: 27626175 Free